NLRC4 methylation and its response to intravenous immunoglobulin therapy in Kawasaki disease : a case control study
© 2024. The Author(s)..
BACKGROUND: Kawasaki disease (KD) is a systemic vasculitis accompanied by many systemic physiological and biochemical changes. Elucidating its molecular mechanisms is crucial for diagnosing and developing effective treatments. NLR Family CARD Domain Containing 4 (NLRC4) encodes the key components of inflammasomes that function as pattern recognition receptors. The purpose of this study was to investigate the potential of NLRC4 methylation as a biomarker for KD.
METHODS: In this study, pyrosequencing was utilized to analyze NLRC4 promoter methylation in blood samples from 44 children with initial complete KD and 51 matched healthy controls. Methylation at five CpG sites within the NLRC4 promoter region was evaluated.
RESULTS: Compared to controls, NLRC4 methylation significantly decreased in KD patients (CpG1: p = 2.93E-06; CpG2: p = 2.35E-05; CpG3: p = 6.46E-06; CpG4: p = 2.47E-06; CpG5: p = 1.26E-05; average methylation: p = 5.42E-06). These changes were significantly reversed after intravenous immunoglobulin (IVIG) treatment. ROC curve analysis demonstrated remarkable diagnostic capability of mean NLRC4 gene methylation for KD (areas under ROC curve = 0.844, sensitivity = 0.75, p = 9.61E-06, 95% confidence intervals were 0.762-0.926 for mean NLRC4 methylation). In addition, NLRC4 promoter methylation was shown to be significantly negatively correlated with the levels of central granulocyte percentage, age, mean haemoglobin quantity and mean erythrocyte volume. Besides, NLRC4 promoter methylation was positively correlated with lymphocyte percentage, lymphocyte absolute value.
CONCLUSIONS: Our work revealed the role of peripheral NLRC4 hypomethylation in KD pathogenesis and IVIG treatment response, could potentially serve as a treatment monitoring biomarker, although its precise functions remain to be elucidated.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
BMC pediatrics - 24(2024), 1 vom: 16. März, Seite 190 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yu, Beirong [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 18.03.2024 Date Revised 19.03.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12887-024-04672-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369828062 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369828062 | ||
003 | DE-627 | ||
005 | 20240319233052.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240317s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12887-024-04672-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1336.xml |
035 | |a (DE-627)NLM369828062 | ||
035 | |a (NLM)38493129 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yu, Beirong |e verfasserin |4 aut | |
245 | 1 | 0 | |a NLRC4 methylation and its response to intravenous immunoglobulin therapy in Kawasaki disease |b a case control study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.03.2024 | ||
500 | |a Date Revised 19.03.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a BACKGROUND: Kawasaki disease (KD) is a systemic vasculitis accompanied by many systemic physiological and biochemical changes. Elucidating its molecular mechanisms is crucial for diagnosing and developing effective treatments. NLR Family CARD Domain Containing 4 (NLRC4) encodes the key components of inflammasomes that function as pattern recognition receptors. The purpose of this study was to investigate the potential of NLRC4 methylation as a biomarker for KD | ||
520 | |a METHODS: In this study, pyrosequencing was utilized to analyze NLRC4 promoter methylation in blood samples from 44 children with initial complete KD and 51 matched healthy controls. Methylation at five CpG sites within the NLRC4 promoter region was evaluated | ||
520 | |a RESULTS: Compared to controls, NLRC4 methylation significantly decreased in KD patients (CpG1: p = 2.93E-06; CpG2: p = 2.35E-05; CpG3: p = 6.46E-06; CpG4: p = 2.47E-06; CpG5: p = 1.26E-05; average methylation: p = 5.42E-06). These changes were significantly reversed after intravenous immunoglobulin (IVIG) treatment. ROC curve analysis demonstrated remarkable diagnostic capability of mean NLRC4 gene methylation for KD (areas under ROC curve = 0.844, sensitivity = 0.75, p = 9.61E-06, 95% confidence intervals were 0.762-0.926 for mean NLRC4 methylation). In addition, NLRC4 promoter methylation was shown to be significantly negatively correlated with the levels of central granulocyte percentage, age, mean haemoglobin quantity and mean erythrocyte volume. Besides, NLRC4 promoter methylation was positively correlated with lymphocyte percentage, lymphocyte absolute value | ||
520 | |a CONCLUSIONS: Our work revealed the role of peripheral NLRC4 hypomethylation in KD pathogenesis and IVIG treatment response, could potentially serve as a treatment monitoring biomarker, although its precise functions remain to be elucidated | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Intravenous immunoglobulin | |
650 | 4 | |a Kawasaki disease | |
650 | 4 | |a Methylation | |
650 | 4 | |a NLRC4 | |
650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
650 | 7 | |a Biomarkers |2 NLM | |
650 | 7 | |a NLRC4 protein, human |2 NLM | |
650 | 7 | |a Calcium-Binding Proteins |2 NLM | |
650 | 7 | |a CARD Signaling Adaptor Proteins |2 NLM | |
700 | 1 | |a Zheng, Bangxu |e verfasserin |4 aut | |
700 | 1 | |a Shen, Yu |e verfasserin |4 aut | |
700 | 1 | |a Shen, Yijing |e verfasserin |4 aut | |
700 | 1 | |a Qiu, Haiyan |e verfasserin |4 aut | |
700 | 1 | |a Wu, Ling |e verfasserin |4 aut | |
700 | 1 | |a Chen, Yuanling |e verfasserin |4 aut | |
700 | 1 | |a Cai, Xiaohong |e verfasserin |4 aut | |
700 | 1 | |a Wu, Junhua |e verfasserin |4 aut | |
700 | 1 | |a Hong, Qingxiao |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC pediatrics |d 2001 |g 24(2024), 1 vom: 16. März, Seite 190 |w (DE-627)NLM111595932 |x 1471-2431 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:16 |g month:03 |g pages:190 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12887-024-04672-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2024 |e 1 |b 16 |c 03 |h 190 |